Lineage Cell Therapeutics, Inc.
General ticker "LCTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $302.4M (TTM average)
Lineage Cell Therapeutics, Inc. follows the US Stock Market performance with the rate: 45.0%.
Estimated limits based on current volatility of 3.7%: low 1.21$, high 1.30$
Factors to consider:
- Total employees count: 77 (+2.7%) as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2022-12-31
- Top business risk factors: Labor/talent shortage/retention, Regulatory and compliance, Manufacturing risks, Manufacturing disruptions, Product liability
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.17$, 2.79$]
- 2026-12-31 to 2027-12-31 estimated range: [1.00$, 2.39$]
Financial Metrics affecting the LCTX estimates:
- Positive: with PPE of -10.8 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: 19.24 < Shareholder equity ratio, % of 39.57 <= 42.59
- Negative: Inventory ratio change, % of 25.12 > 0.78
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -3.48 <= -0.60
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
Short-term LCTX quotes
Long-term LCTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $8.95MM | $9.50MM | $14.56MM |
| Operating Expenses | $33.68MM | $30.98MM | $51.17MM |
| Operating Income | $-24.73MM | $-21.48MM | $-36.62MM |
| Non-Operating Income | $1.45MM | $2.90MM | $-32.03MM |
| R&D Expense | $15.71MM | $12.47MM | $17.73MM |
| Income(Loss) | $-23.28MM | $-18.58MM | $-68.65MM |
| Taxes | $-1.80MM | $0.00MM | $-5.28MM |
| Net Income(Loss)* | $-21.49MM | $-18.61MM | $-63.53MM |
| Stockholders Equity | $63.42MM | $78.38MM | $44.55MM |
| Assets | $101.02MM | $113.22MM | $112.58MM |
| Operating Cash Flow | $-28.57MM | $-23.09MM | $-18.92MM |
| Capital expenditure | $0.67MM | $0.56MM | $0.52MM |
| Investing Cash Flow | $46.45MM | $-2.31MM | $-13.46MM |
| Financing Cash Flow | $6.42MM | $35.86MM | $26.95MM |
| Earnings Per Share** | $-0.12 | $-0.09 | $-0.28 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.